AIONE Raises $7M Series A Funding

Laverock Therapeutics

Next generation programmable cell therapies

GNOSIS Health Limited

Gnosis Health is a digital health spinout from Newcastle University developing tools for Parkinson’s disease management. Its platform, MAXine, integrates a patient app, conversational AI, and wearables to enable real-time symptom tracking and personalised insights. The company targets the self-pay healthtech market through direct-to-consumer subscriptions, with additional revenues from pharma and providers. Gnosis has completed clinical trials, secured NHS pilot partnerships, is a certified medical device, holds a growing patent portfolio, and has Innovate UK funding and HMRC Advance Assurance. The company is now scaling to other chronic conditions and global markets, with early commercial traction and inbound demand.

Board

Board’s Enterprise Planning Platform delivers solutions that help over 2,000 organizations worldwide plan smarter — enabling actionable insights and better outcomes. Board helps leading enterprises discover crucial insights which drive business decisions and unify strategy, finance and operations through more integrated and intelligent planning to achieve full control of performance. Partnering with Board, global enterprises such as H&M, BASF, Burberry, Toyota, Coca-Cola, Kraft Heinz, and HSBC have deployed end-to-end planning applications at a fraction of the time and cost associated with traditional solutions. Board International was founded in 1994 and now has 25 offices around the world and a global reseller network. Board has been implemented in over 100 countries. Board International has long been recognized by leading analysts and subject matter experts including Gartner, Nucleus, and Dresner. Headquartered in Switzerland and US, Board International has branches in Argentina, Australia, Benelux, Nordics, Germany, France, India, Italy, Japan, Mexico, Singapore, Spain, UAE and UK and a worldwide network of distributors and certified partners. Board International is an equal opportunity employer and is committed to a diverse and inclusive workforce.

KOSMOS

When something breaks, your team spends hours investigating what happened across Jira, Salesforce, GitHub, and ServiceNow before they can fix anything. Kosmos connects those signals automatically, surfaces root cause in seconds, and reduces MTTR and repeat incidents. Every correlation is proposed by machine, confirmed by human, and learned by the system.

NewLimit

NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale. All correspondence from NewLimit will come from an @NewLimit.com email address.